| | Liver 
Enzyme Elevations in HIV Positive Individuals with Occult Hepatitis B Virus Infection
 
 The 
clinical significance of occult hepatitis B virus (HBV) 
infection -- that is, the presence of HBV DNA in individuals with HBV core 
antibodies (anti-HBc) in the absence of HBV surface antigen (HBsAg) -- is unclear 
in HIV positive patients, and thus it is uncertain 
whether low-level HBV needs to be detected and treated in this population. 
 As 
described in the September 2008 Journal of Clinical Virology, Vincent Lo 
Re and colleagues from the University of Pennsylvania School of Medicine conducted 
a study to determine if HIV positive individuals with occult HBV infection have 
an increased incidence of liver enzyme elevation.
 Elevated 
alanine and aspartate transaminase (ALT and AST, respectively) -- sometimes known 
as "transaminitis" -- is an indicator of liver inflammation, which may 
signal hepatitis B or C 
disease progression, drug-induced liver toxicity, or other liver problems.
 This 
cohort study included 97 randomly selected HIV positive patients in the Penn CFAR 
Database and Specimen Repository who were HBsAg negative and anti-HBc positive. 
HBV DNA was qualitatively detected using a transcription-mediated amplification 
assay. Liver transaminase levels were measured at 6 month intervals from the time 
of occult HBV determination.
 
 Results
 
 
       
Among the 97 randomly selected participants without elevated transaminase levels 
at baseline, 13 (13%) had occult HBV. 
  
       
These patients more frequently had detectable HIV RNA.
 
  
       
The 2-year incidence of elevated liver enzymes among HIV-infected participants 
with occult HBV was not significantly different from that of patients without 
occult HBV (50 vs 38 events per 100 person-years, respectively; adjusted incidence 
rate ratio 1.36).
 
 
 Based 
on these findings, the investigators concluded, "Occult HBV did not increase 
the incidence of hepatic transaminitis over 2 years."
 They added that, 
"Future studies should determine whether occult HBV is associated with other 
clinically important outcomes, particularly hepatocellular 
carcinoma."
 
 Division of Infectious Diseases, University of 
Pennsylvania School of Medicine, Philadelphia, PA; Department of Biostatistics 
and Epidemiology, Center for Clinical Epidemiology and Biostatistics, University 
of Pennsylvania School of Medicine, Philadelphia, PA; Center for Education and 
Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, 
PA.
 
 
  10/17/08 
 Reference
 V 
Lo Re, B Wertheimer, AR Localio, and others. Incidence of transaminitis among 
HIV-infected patients with occult hepatitis B. Journal of Clinical Virology 
43(1): 32-36. September 2008. (Abstract).
        | 
 |  
|  |  |  
| 
 | | FDA-approved 
Therapies for Chronic HBV Infection | 
 | 
   |  | Protease 
Inhibitors |  |  |  | Nucleoside 
/ Nucleotide  Reverse Transcriptase Inhibitors |  |  |  | non 
Nucleoside Reverse Transcriptase Inhibitors
 |  |  |  | Entry 
Inhibitors (including Fusion Inhibitors)
 |  |  |  | Fixed-dose 
Combinations |  | | Atripla 
(efavirenz + emtricitabine + tenofovir) Combivir 
(zidovudine + lamivudine)Trizivir 
(abacavir + zidovudine + lamivudine)Truvada 
(tenofovir + emtricitabine) | 
 |  | Integrase 
Inhibitor |  |  |                                                                                                                            |  |